Successful preliminary trials incorporating CAR-iNKT therapy have targeted a variety of cancer-specific antigens including CD19 (61), B cell maturation antigen (BCMA) (62), and GD2 (63) for treatment of B cell lymphoma, multiple myeloma, and neuroblastoma, respectively (Table 2). Here, TNFRSF17 is linked to cancer.